Exciting updates and more details about my journey with SynPlexity coming soon. Stay tuned!

In my role at KCASI, working within the dynamic environment of the Plesa Laboratory, I am deeply involved in pioneering research and development efforts that are reshaping our understanding and capabilities in biological protein-based systems. My work spans a diverse range of applications and responsibilities:• Gene Synthesis: Specializing in the development of innovative gene assembly methods, scaling techniques, and enabling technologies to significantly advance the field of synthetic biology.• Technology Readiness: Focused on advancing technologies from conceptual stages to market readiness, ensuring they meet industry standards and requirements.• Industry Perspective: Offering valuable insights and perspectives to lab members, bridging the gap between academic research and industry applications.• IP Development: Actively involved in the creation and management of intellectual property, contributing to the strategic development and protection of innovative biotechnological advancements.At the heart of our efforts is the goal to accelerate the pace of scientific discovery and impact in various research areas. By developing and applying cutting-edge technologies in gene synthesis and functional assays, we aim to unlock new possibilities in biological engineering and contribute significantly to the field's advancement.

At Concept Bio Consulting, my role extends beyond traditional biotechnology consulting, encompassing a wide spectrum of expertise in bioconjugation, chemistry, proteomics, next-generation sequencing (NGS), single-cell analysis/genomics, microfluidics, and nanotechnology. I specialize in offering strategic insights and technical assessments to various biotechnology companies, aiding in market analysis, technology development, and navigating the complexities of product innovation.A significant aspect of my work involves collaborating with venture capitalists and investment firms, providing them with expert input on potential biotech ventures. My guidance helps these firms make informed decisions on investments, leveraging my extensive knowledge in biology, materials science, and chemistry.I also engage closely with start-up enterprises, advising them on product development strategies and market entry. My comprehensive approach addresses the unique challenges in the biotech sector, assisting companies in innovating and achieving success in a competitive landscape.

As the leader of both the Formulations and Nanotechnology team and the Advanced Analytical team at Seer, I spearheaded chemical and materials innovations to advance state-of-the-art proteomics. My role was pivotal in driving the company towards a successful IPO, raising $175M in capital and achieving a market valuation of $1.3B

Key Achievements:• Strategically led the Formulations and Nanotechnology Team, playing a critical role in the company's successful IPO.• Oversaw the development of a technical portfolio comprising over 270 nanomaterials and secured 5 invention disclosures.• Gained a deep understanding of valuation methodologies and competitive intelligence tools, including PatSnap and SciFinder.• Reported directly to the VP and CEO, focusing on technical strategy. I was responsible for executing market analysis and competitive landscape assessments, identifying risks and opportunities, and developing alternate scenarios.• Created and developed new competitive and market intelligence databases, dashboards, and analyses, enhancing the company's strategic decision-making capabilities.• Conceptualized and developed biomaterials platforms for protein detection and analysis. I also pioneered modular synthesis platforms and conceptualized 15 new applications for Seer’s Proteograph platform.• Led the development of a nanomaterials panel, overseeing the design and development of the nanotechnology platform and the nanomaterials characterization program.• Recruited and mentored a nanomaterials research team comprising 6 PhD scientists and 1 MS level scientist, revolutionizing nanomaterial science. I also led and mentored cross-functional teams, fostering collaboration with key stakeholders.

• Critical contributor to development of $20M Polaris single cell analysis system, generating $8M in annual revenue. Oversaw materials development for microfluidic logic system for single cell applications• Developed innovative microgels for droplet based RNA-seq application, surface immobilization strategy for novel sequencing platform, and novel surface coating methodologies for “in chip” modification• Developed novel microfluidic circuit which enables rapid screening of biochemistry and surface chemistry without use of expensive microfluidic circuit / test chip format• Led as Project manager for three key technology transfer projects, reporting directly to VP of R&D. Spearheaded design and testing of microfluidic integrated circuit for end-point genotyping assay• Developed surface chemistry and materials integration including the modification of PDMS and glass surfaces• Conceptualized novel polymer systems for microfluidic chips, including PDMS, acrylate, polyurethane. Developed materials for microfluidic multiomic capture and purification chip (DNA, RNA and protein capture)• Collaborated with Microfluidics and Engineering, Process Development, and Manufacturing teams; worked closely with the marketing team to assess the microbiome and gene editing market• Poster selected for Fluidigm’s 2017 Innovation Day: CRISPR/Cas9 Workflows and IFC. Earned role on Technology Landscape Development Team for technical contributions on materials, chemistry, and applications in 2016

• Critical contributor on a team that commercialized two semiconductor sequencing platforms (PGM, Proton-1), generating an estimated $100M in annual revenue. Subsequent work enabled launch of Apliseq product line, resulting in $10M annual revenue• Major contributor to research and development of a semiconductor sequencing platform with a focus on microgel development, bioconjugation and surface chemistry/analysis• Oversaw advanced materials characterization methods for microgels, developing IP on novel bioconjugation methods. Drove embodiment for Proton-1 platform. Developed a novel method for creating DNA that is soluble in organic solvents• Nucleic acid assay development, target hybridization methodologies, and quantitative assays for conjugated DNA• Developed multiple novel bioconjugation routes for conjugating DNA and biomolecules to microgels, nanoparticles and surfaces (metal oxides, glass). Recognized for major contributions and outstanding technical reports• Developed microgel and semiconductor surface characterization and analysis• Executed PCR and isothermal DNA amplification techniques• Collaborated extensively with manufacturing and process development teams• Poster selected for Life Technologies 2014 Science and Technology Symposium. Earned Silver Award for Process and scalability; 2-time Bronze award winner and 5-time milestone award recipient for meeting and exceeding PI program milestones• Significant contributions to the Ampliseq platform development with enhanced sequencing coverage and throughput, resulting in the commercialization of the Ampliseq kit with throughput exceeding 15G, P-II throughput milestone 32G, and P-II throughput milestone 42G• 4-time recipient of “spot level” awards as well as 2014 Q1 Leading contributor to the technical confluence. Noted for outstanding contributions for the AGBT presentation as well as successful achievement of a major product development milestone

• Significant contributor to research and development of a single molecule DNA sequencing platform based on FRET with a focus on small molecule synthesis, bioconjugation, surface chemistry and surface analytics• Developed novel coating methods that became a new line of labeling and detection reagents, generating $20M in annual revenue• Established advanced characterization methods for nanocrystal platform (NMR)• Developed novel ligand exchange methodologies• Nanocrystal synthesis and analysis as well as synthesis of small molecule ligands and biocompatible polymers specifically designed for fluorescent nanocrystal coating• Developed a novel one pot polymer synthesis and simultaneous nanocrystal coating process• Developed analytical techniques for nanocrystal surface quantitative and qualitative analysis: XPS and NMR (high resolution,DOSY)• Developed novel bioconjugation routes for single polymerase-nanocrystal conjugates. Also developed fluorescence assay• Collaborated extensively with the Project Management team; served as a pivotal member of the Bioconjugation task force• Earned “Betelgeuse Award” for outstanding contributions to program milestone achievement as well as the “Orion Award,” a team award for outstanding technical contributions. Poster selected for 2010 Life Technologies Science and Technology Symposium. 3-time recipient of “spot level” awards for outstanding technical contributions

• Led research and development of novel high-performance polymer systems. Lead author for several profitable, novel patents, generating high growth product line with revenues over $410M over 12 years• Developed portfolio of novel products, generating $30M/year franchise with market-oriented approach• Thought leader and technical marketing leader of Railroad Products Group. Created new business unit, Railroad Products, at firm that generated over $35M in annual revenue• Partnered with customer to develop new testing strategies that resulted in customer savings of $2M/year• Directed technical work in product development and materials systems for railroad repair. Managed team of 3 MS-level bench chemists. Led as project manager for numerous product releases as well as line item extension• Developed microbead surface modification and analysis. Directed surface chemistry, surface analysis and polymer characterization (XPS, SIMS, SEM, NMR, DMA). Oversaw design and testing for coating and sealants• Directed materials testing including lifetime and durability assessments using large scale load frames. Developed adhesives system development and testing• Collaborated with sales, marketing, manufacturing and technical service teamson release of three critical products; directly reported to VP of Business Unit